Boston Scientific to acquire Axonics for $3.7B, expanding urology portfolio into sacral neuromodulation

BOSTON SCIENTIFIC CORP

Purchase price of $71 per share cash; equity value ~$3.7B, enterprise value ~$3.4B.
Axonics 2023 revenue ~$366M (+34% YoY); deal expected to close H1 2024.
Axonics offers SNM therapy for overactive bladder and fecal incontinence with Axonics R20 neurostimulator (20+ year battery).
Deal expected to be immaterial to BSX adjusted EPS in 2024, accretive thereafter.
Expands BSX urology portfolio into high-growth SNM adjacency, targeting ~30M OAB patients in US.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.